Blue Wolf Capital Acquires Seven Recipharm OSD Sites and Agrees to Buy Synerlab to Create New CDMO Platform

Recipharm AB Acquires Vibalogics from Ampersand Capital Partners

February 18, 2022

Biotechnology

Recipharm AB, a global CDMO based in Sweden, has agreed to acquire Vibalogics, a virotherapy-focused CDMO and Ampersand Capital Partners portfolio company. The deal expands Recipharm's capabilities into viral vaccines, viral vectors and oncolytic virus manufacturing while Vibalogics will continue operating from its Boxborough, MA and Cuxhaven, Germany facilities.

Servier Acquires Symphogen A/S from Novo Holdings and Other Owners

April 3, 2020

Biotechnology

Servier has acquired 100% of the share capital of Symphogen A/S from Novo Holdings and the remaining owners, taking ownership of the Danish therapeutic antibody discovery and early biologics development company. The deal brings Symphogen’s antibody discovery platform and CMC biologics development capabilities into Servier’s oncology and immuno-oncology R&D efforts to strengthen its biologics pipeline and development capacity.

Omnicell Acquires Pharmaceutical Strategies Group's 340B Link Business from Blue Wolf Capital

October 2, 2020

Healthcare Services

Omnicell, Inc. has acquired Pharmaceutical Strategies Group's market-leading 340B Link business from Blue Wolf Capital Partners for $225 million. The deal, which completes Blue Wolf's exit of PSG from Fund II, expands Omnicell's medication management and data-enabled services for hospitals and pharmacies.

Recro Pharma Acquires IRISYS (San Diego)

August 13, 2021

Pharmaceuticals

Recro Pharma (NASDAQ: REPH) acquired San Diego–based CDMO IRISYS for approximately $49.85 million in cash, stock and a seller promissory note, transforming Recro into a bi‑coastal, full‑service CDMO. The acquisition expands Recro's capabilities (including aseptic fill/finish and lyophilization), diversifies its client base and adds near‑term revenue and backlog.

SK Capital Acquires Catalent's Blow‑Fill‑Seal Sterile CDMO Business (Woodstock Sterile Solutions)

March 31, 2021

Pharmaceuticals

Funds managed by SK Capital Partners completed the acquisition of Catalent Pharma Solutions' Blow‑Fill‑Seal (BFS) sterile CDMO business and relaunched the business as Woodstock Sterile Solutions. The single‑site Woodstock, Illinois operation will operate independently under new CEO Paul Josephs, supporting global pharmaceutical and biologics customers; Catalent was the seller and debt financing was provided by Cerberus Business Finance.

Revelation Pharma (Osceola Capital) Acquires Five Compounding Pharmacies

January 27, 2022

Healthcare Services

Revelation Pharma, a PE-backed specialty pharmacy platform sponsored by Osceola Capital, completed add-on acquisitions of five compounding pharmacies: Innovation Compounding, Pencol Compounding Pharmacy, Pharmacy Specialists Compounding, Wise Pharmacy, and Convex Pharmacy. The deals expand Revelation's geographic footprint and clinical capabilities across key U.S. regions and will see some locations merged into existing Revelation businesses (e.g., Wise into Pencol; Convex into Everwell).